福巴替尼(Futibatinib) - 药物靶点：FGFR1 x FGFR2 x FGFR3 x FGFR4_在研适应症：FGFR2融合或重排的胆管癌，肝内胆管癌，胆道癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Futibatinib (JAN/USAN/INN)、TAS 120、TAS-120

+ [2]

靶点

FGFR1 x FGFR2 x FGFR3 x FGFR4

作用方式

拮抗剂

作用机制

FGFR1拮抗剂(成纤维细胞生长因子受体-1拮抗剂)、FGFR2拮抗剂(成纤维细胞生长因子受体-2拮抗剂)、FGFR3拮抗剂(成纤维细胞生长因子受体-3拮抗剂)

治疗领域

肿瘤消化系统疾病其他疾病+ [5]

在研适应症

FGFR2融合或重排的胆管癌肝内胆管癌胆道癌+ [21]

非在研适应症

KRAS突变胰腺癌非小细胞肺癌

原研机构

Taiho Pharmaceutical Co., Ltd.

在研机构

Taiho Oncology, Inc.

Taiho Pharmaceutical Co., Ltd.Merck Sharp & Dohme LLC

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2022-09-30),

肝内胆管癌

最高研发阶段(中国)临床2期

特殊审评优先审评 (美国)、突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (澳大利亚)、附条件批准 (欧盟)

登录后查看时间轴

结构/序列

分子式C22H22N6O3

InChIKeyKEIPNCCJPRMIAX-HNNXBMFYSA-N

CAS号1448169-71-8

关联

32

项与福巴替尼相关的临床试验

NCT06722183

/ Not yet recruiting临床2期IIT

FUTURE Platform Trial - A Phase II Platform Trial of Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

The FUTURE trial is a prospective, multicentre, exploratory, open-label phase II platform trial. Its goal is to evaluate the efficacy, feasibility and safety of futibatinib combined with immunotherapeutic, targeted or chemotherapeutic agents in colorectal and other solid tumors and to additionally identify biomarkers that correlate with clinical outcome.

开始日期2025-03-01

申办/合作机构

Institut fr Klinische Krebsforschung IKF GmbH

NCT06263153

/ Recruiting临床2期IIT

A Phase II Trial of Futibatinib in Combination with Durvalumab (MEDI4736) Administered to Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer Before Cystectomy

This phase II trial tests how well the combination of futibatinib and durvalumab given before cystectomy works in treating patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based therapy. Cisplatin-based therapy is the standard of care for patients with MIBC. However, many patients cannot receive standard therapy due to poor renal function, peripheral neuropathy, poor functional status, or clinically significant heart failure. Futibatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Radical cystectomy is a surgery to remove all of the bladder as well as nearby tissues and organs. Giving futibatinib in combination with durvalumab before surgery may be an effective treatment option for patients with MIBC who are ineligible for cisplatin-based therapy.

开始日期2024-12-30

申办/合作机构

Ohio State University Comprehensive Cancer Center

[+1]

CTIS2024-512217-40-00

/ Recruiting临床2/3期

An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study - TAS-120-404

开始日期2024-10-21

申办/合作机构

Taiho Oncology, Inc.

100 项与福巴替尼相关的临床结果

登录后查看更多信息

100 项与福巴替尼相关的转化医学

登录后查看更多信息

100 项与福巴替尼相关的专利（医药）

登录后查看更多信息

141

项与福巴替尼相关的文献（医药）

2025-04-01·MOLECULAR DIVERSITY

Targeting AFP-RARβ complex formation: a potential strategy for treating AFP-positive hepatocellular carcinoma

Article

作者: Dev, Radul R ; Soman, Sowmya ; Banjan, Bhavya ; Raju, Rajesh ; Vishwakarma, Riya ; Kalath, Haritha ; Rehman, Niyas ; Revikumar, Amjesh ; Kumar, Pankaj ; Abhinand, Chandran S ; Ramakrishnan, Krishnapriya

Alpha-fetoprotein (AFP) is a glycoprotein primarily expressed during embryogenesis, with declining levels postnatally. Elevated AFP levels correlate with pathological conditions such as liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Recent investigations underscore AFP's intracellular role in HCC progression, wherein it forms complexes with proteins like Phosphatase and tensin homolog (PTEN), Caspase 3 (CASP3), and Retinoic acid receptors and Retinoid X receptors (RAR/RXR). RAR and RXR regulate gene expression linked to cell death and tumorigenesis in normal physiology. AFP impedes RAR/RXR dimerization, nuclear translocation, and function, promoting gene expression favoring cancer progression in HCC that provoked us to target AFP as a drug candidate. Despite extensive studies, inhibitors targeting AFP to disrupt complex formation and activities remain scarce. In this study, employing protein-protein docking, amino acid residues involved in AFP-RARβ interaction were identified, guiding the definition of AFP's active site for potential inhibitor screening. Currently, kinase inhibitors play a significant role in cancer treatment and, the present study explores the potential of repurposing FDA-approved protein kinase inhibitors to target AFP. Molecular docking with kinase inhibitors revealed Lapatinib as a candidate drug of the AFP-RARβ complex. Molecular dynamics simulations and binding energy calculations, employing Mechanic/Poisson-Boltzmann Surface Area (MM-PBSA), confirmed Lapatinib's stability with AFP. The study suggests Lapatinib's potential in disrupting the AFP-RARβ complex, providing a promising avenue for treating molecularly stratified AFP-positive HCC or its early stages.

2025-04-01·ANNALS OF ONCOLOGY

Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling

Article

作者: Bridgewater, J A ; Meric-Bernstam, F ; Okamura, S ; Silhavy, J L ; Hollebecque, A ; Kano, A ; Halim, A ; DiToro, D ; Shimura, M ; Goyal, L ; Wacheck, V

BACKGROUND:

Futibatinib is the only covalent inhibitor of FGFR1-4 to gain regulatory approval in oncology. In this article, we present genomic analyses of tissue biopsies and circulating tumor DNA (ctDNA) from patients with 1 of nearly 20 tumor types treated with futibatinib in the phase I/II FOENIX study.

PATIENTS AND METHODS:

Eligible patients included those with ctDNA samples collected per protocol at baseline and/or progression on futibatinib in the phase Ib portion of the study for FGF/FGFR-altered advanced solid tumors or the phase II portion of the study for FGFR2 fusion/rearrangement-positive cholangiocarcinoma. Assessments included analytical concordance between tumor and ctDNA analyses for detection of FGFR alterations, association of ctDNA-detected co-occurring genomic alterations with response to futibatinib, and determination of patterns of acquired resistance following progression on futibatinib.

RESULTS:

Among 300 patients treated with futibatinib, 226 were eligible for this analysis, including 139 (62%) with cholangiocarcinoma. Among patients with known FGFR2 fusions/rearrangements, FGFR1 fusions, FGFR3 fusions, or FGFR2 amplifications per tissue analysis, detection rates in ctDNA for these aberrations were 84%, 0%, 11%, and 59%, respectively. Objective response rates on futibatinib were not significantly different between patients with TP53-altered versus -unaltered solid tumors; progression-free survival was reduced in patients with CDKN2B-altered versus -unaltered cholangiocarcinoma (median 4.8 versus 11.0 months; P = 0.03). Acquired resistance to futibatinib was frequently polyclonal and driven by an array of mutations within the relevant FGFR kinase domain, predominantly V565L, V565F, and N550K variants.

CONCLUSIONS:

In this largest and most systematic analysis of acquired resistance to an FGFR inhibitor from prospective clinical trials, emergence of secondary FGFR2 kinase domain mutations was observed in most patients receiving clinical benefit to futibatinib. ctDNA analysis shows clinically relevant potential as a noninvasive method for assessing genomic profiles, identifying patients who may benefit from FGFR inhibitor treatment, and exploring acquired resistance mechanisms.

2025-03-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis, and biological evaluation of a potent and orally bioavailable FGFRs inhibitor for fibrotic treatment

Article

作者: Xie, Yuting ; Wei, Wei ; Wu, Xiuli ; Liu, Hongyao ; Tan, Zui ; Gan, Cailing ; Ye, Tinghong ; Su, Xingping ; Xue, Taixiong ; Li, Peilin ; Yue, Lin ; Liu, Zhihao ; Wang, Doudou

Organ fibrosis, such as lung fibrosis and liver fibrosis, is a progressive and fatal disease. Fibroblast growth factor receptors (FGFRs) play an important role in the development and progression of fibrosis. Through scaffold hopping, bioisosteric replacement design, and structure-activity relationship optimization, we developed a series of highly potent FGFRs inhibitors, and the indazole-containing candidate compound A16 showed potent kinase activity comparable to that of AZD4547. In addition, A16 effectively suppressed the activation of lung fibroblasts and hepatic stellate cells (HSCs) induced by TGF-β1, leading to a reduction in collagen deposition. Notably, A16 exhibited potent anti-fibrotic effects through the inhibition of the FGFR pathway in vitro. Compound A16 also showed reasonable pharmacokinetic properties (F = 21.84 %) and favorable cardiac safety (hERG IC₅₀ > 20 μM). Moreover, in models of pulmonary fibrosis, A16 ameliorated (in the prevention model) and reversed (in the treatment model) bleomycin-induced lung fibrosis, as well as mitigated inflammatory immune response in the lung. Furthermore, in the CCl₄-induced liver fibrosis model, when A16 was administrated orally at a dose of 30 mg/kg/day for 3 weeks, it effectively improved liver function, restored damaged liver structures, and reduced collagen deposition. Taken together, these results suggest that A16 could be a potential drug candidate for the treatment of organ fibrosis.

63

项与福巴替尼相关的新闻（医药）

2025-03-28

·FiercePharma

Fierce Pharma Asia—Novo's triple G obesity bet; Merck's latest China deal; Hengrui, Elevar's 2nd FDA snub

Novo Nordisk's China obesity deal, Merck's cardiovascular licensing deal, and an FDA rejection for Hengrui and Elevar's PD-1 combo made our news this week. Novo Nordisk snapped up an obesity asset from China's United Laboratories in a deal worth up to $2 billion. Merck & Co. got a lipoprotein(a) inhibitor from Jiangsu Hengrui Pharma for cardiovascular disease. Hengrui and Elevar Therapeutics' PD-1 liver cancer combination was again tripped up by manufacturing at the FDA.1. Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeksNovo Nordisk has bought into the “triple G” idea, gaining a GLP-1/GIP/glucagon triple agonist from China’s United Laboratories for up to $2 billion. The candidate, coded UBT251, would be a direct competitor to Eli Lilly’s retatrutide. In a phase 1b trial, weekly UBT251 at the highest subcutaneous dose of 6 mg led to an average 15.1% weight loss from baseline after 12 weeks.2. Merck & Co. pens $200M upfront deal for Hengrui's midstage heart disease medIn another China deal potentially worth up to $2 billion, Merck & Co. is paying $200 million upfront for a phase 2 lipoprotein(a) inhibitor from Hengrui Pharma. Elevated Lp(a) in the blood, as a risk factor for cardiovascular disease, has become an increasingly popular target. Lilly has a clinical candidate called muvalaplin, and AstraZeneca last year licensed a preclinical one from China’s CSPC Pharma.3. FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—againIn a piece of bad news for Hengrui, the FDA has once again rejected its Elevar Therapeutics-partnered combination of the PD-1 inhibitor camrelizumab and VEGFR inhibitor rivoceranib. Like the first rejection last year, the FDA this time also raised problems with Hengrui’s camrelizumab manufacturing facility in China.4. AbbVie takes Genmab to court, accusing partner of being 'willfully blind' to ADC trade secret theftAbbVie has sued Genmab over the Danish company’s $1.8 billion acquisition of Sino-American biotech ProfoundBio last year. The Illinois pharma alleged that Genmab was “intentionally and willfully blind” to Profound’s alleged theft of its antibody-drug conjugate trade secrets. Genmab said it “categorically refutes allegations and will vigorously defend the company.”5. J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca's TagrissoJohnson & Johnson’s Rybrevant and its Yuhan-partnered Lazcluze significantly reduced the risk of death by 25% versus AstraZeneca’s Tagrisso in first-line EGFR-mutated non-small cell lung cancer, according to a high-stakes readout from the phase 3 Mariposa trial. J&J believes the overall survival win sets the combo up to be the new standard of care. But the high-maintenance nature of the regimen poses a challenge.6. Drugmakers fear Trump tariffs will drive up manufacturing costs, hurt medicine access: BIO surveyTrump again threatens tariffs on pharmaceuticals in 'not too distant' futurePresident Donald Trump said his administration will announce tariffs on pharmaceuticals “in the not too distant” future. But in a recent survey conducted by the Biotechnology Innovation Organization, a large proportion of biopharma companies polled said tariffs on EU, Canada or China will drive up manufacturing costs. Many respondents also fear that tariffs could disrupt R&D and regulatory plans.7. FDA calls out 'particularly concerning' claims on HCP site for Taiho's LytgobiThe FDA has taken issue with Taiho Oncology’s doctor-facing web page for the cholangiocarcinoma drug Lytgobi. The agency raised concerns that some descriptions of the drug’s overall survival and progression-free survival data from a single-arm phase 2 study were misleading. The agency is giving the firm 15 working days to submit a written response.8. Eisai lays out road map to blockbuster sales projections for Leqembi's 'milestone' 2027 year9. Contractors WuXi Bio, WuXi XDC eye continued growth after logging solid performances in 202410. Gavi terminates COVID vaccine deal with Clover, demands $224M repayment11. Ascletis slashes funding for former core programs in pivot to obesity12. ImmuneOnco axes CD47 bispecific as pipeline prioritization pressures hit Chinese biotech13. India's Aspen Biopharma Labs hit with FDA warning letter citing infrastructure, contamination and records problems14. Biotech designed to commercialize Ascendis' endocrinology drugs in China files $86M IPO15. Bharat Biotech enters cell and gene therapy market with $75M production investment: reports16. Bayer gains Puhe’s cancer drug candidate in another China deal (release)17. Kaken agrees to $180M deal to develop Alumis' lead TYK2 inhibitor in Japan

疫苗临床2期临床1期临床结果临床3期

2025-03-26

·EndPoints

FDA critiques Taiho Oncology's 'misleading' promotional website for bile duct cancer drug

The FDA is taking issue with a promotional website from Taiho Oncology, alleging it misleadingly describes the benefits of its bile duct cancer drug Lytgobi, which won accelerated approval in 2022. The untitled letter sent last week calls out the way the company’s website offers allegedly misleading interpretations of efficacy in the single-arm trial on which the accelerated approval was based. The agency said certain efficacy-related parts of the webpage misbrand Lytgobi “by misleadingly suggesting that FOENIX-CCA2,” a Phase 1/2 study in 103 patients , “provided interpretable results regarding the effects of Lytgobi on PFS [progression-free survival] and OS [overall survival] endpoints.” Because FOENIX-CCA2 was designed as a single-arm trial, with no comparator arm, the FDA added, “the reported PFS and OS results are uninterpretable; absent an appropriate comparator, it is not possible to determine if the observed effect is attributable to Lytgobi or to other factor(s), such as the natural history of the disease.” The FDA acknowledged that Taiho said the data presented on its site should be interpreted with caution, but noted that such statements do “not render the promotional communication nonmisleading in light of the issues with FOENIX-CCA2.” Presentations on the website are also “misleading by suggesting that Lytgobi improves DCR [disease control rate] in patients with locally advanced or metastatic iCCA [intrahepatic cholangiocarcinoma] based on a composite of complete response (CR), partial response (PR), and stable disease (SD) when the study from which the presentations were drawn could not demonstrate this result,” the agency said. In a statement to Endpoints News , Taiho said it worked to present data “in a manner that is truthful and not misleading and consistent with FDA guidelines” and was “reviewing their comments and will respond appropriately and in a timely manner.” This is the second untitled letter this year from the FDA’s Office of Prescription Drug Promotion to industry.

加速审批

2025-03-17

·FierceBiotech

Otsuka\'s Taiho pays $400M for Swiss partner to \'turbocharge\' 3 ADCs to clinic

Taiho Pharmaceutical\'s \"significant cancer expertise will support us in turbocharging the clinical development of our potent ADC candidates in hematological and solid tumors,” Araris Biotech\'s CEO said.\n Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC) linker platform.The two companies have been working together since November 2023, when Araris agreed to use its AraLinQ platform to develop ADCs aimed at Taiho’s targets of choice. Taiho presumably liked what it saw, as the biotech has now decided to go all-in and buy Araris.The deal will see Taiho hand over $400 million, with Araris’ shareholders potentially in line for a further $740 million in milestone payments, according to a March 17 release.Araris has its origins in Switzerland’s Paul-Scherrer-Institute, before spinning off in 2019. The biotech is focused on designing ADCs that have greater linker solubility, with three preclinical therapies aimed at hematological and solid tumors expected to enter human trials over the course of 2025 and 2026.Araris touts its linker tech as having three benefits over its competitors. Firstly, the attachment site on a specific amino acid within the antibody IgG-Fc framework means the antibody maintains almost the same performance when part of the ADC. Meanwhile, the strong peptide bond connecting the linker antibody to the therapy’s payload results in “exceptional stability in the blood stream and therefore, avoidance of healthy tissue damage,” according to the release. This bond then breaks easily inside a cancer cell.“Araris’ unique ADC technology represents a quantum leap for the ADC field, potentially offering precise payload delivery of multiple mechanisms of action simultaneously to the tumor, with less toxicity,” CEO and co-founder Dragan Grabulovski said. “We are proud to combine with Taiho, our partner since November 2023, whose significant cancer expertise will support us in turbo-charging the clinical development of our potent ADC candidates in hematological and solid tumors.”Taiho is a subsidiary of Japan’s Otsuka and markets a wide range of anticancer drugs in the country. In the U.S., the subsidiary has three FDA-approved products: the colorectal treatment Lonsurf, the bile duct cancer med Lytgobi and the myelodysplastic syndromes treatment Inqovi.Using Araris’ ADC drug tech alongside Taiho’s own small-molecule drug discovery platform Cysteinomix will allow Taiho to “further expand its ongoing development portfolio in the field of oncology,” according to this morning’s release.ADCs have been one of the hottest spaces for dealmaking in recent years, with the likes of AstraZeneca, Roche, Merck & Co. and Ipsen all posting billion-dollar-plus biobucks pacts.

$Otsuka\'s Taiho pays $400M for Swiss partner to \'turbocharge\' 3 ADCs to clinic$

抗体药物偶联物上市批准并购

100 项与福巴替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11725	-	-	DB15149

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
FGFR2融合或重排的胆管癌	日本	Taiho Pharmaceutical Co., Ltd.	2023-06-26
肝内胆管癌	美国	Taiho Oncology, Inc.	2022-09-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胆道癌	申请上市	日本	Taiho Pharmaceutical Co., Ltd.	2022-01-30
肿瘤转移	临床3期	美国	Taiho Oncology, Inc.	2024-10-01
肿瘤转移	临床3期	法国	Taiho Oncology, Inc.	2024-10-01
肿瘤转移	临床3期	西班牙	Taiho Oncology, Inc.	2024-10-01
肿瘤转移	临床3期	英国	Taiho Oncology, Inc.	2024-10-01
食管腺癌	临床2期	美国	Taiho Oncology, Inc.	2023-07-13
食管腺癌	临床2期	法国	Taiho Oncology, Inc.	2023-07-13
食管腺癌	临床2期	德国	Taiho Oncology, Inc.	2023-07-13
食管腺癌	临床2期	西班牙	Taiho Oncology, Inc.	2023-07-13
食管鳞状细胞癌	临床2期	美国	Taiho Oncology, Inc.	2023-07-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04093362 (FOENIX-CCA3, CTgov)	临床3期	FGFR2融合或重排的胆管癌	10	Futibatinib	觸窪艱選願襯醖憲蓋齋 = 蓋簾願夢糧艱憲淵鹽憲餘構獵憲齋選餘築範鹽 (鏇鏇鬱獵齋願製壓醖憲, 選壓襯壓願願蓋淵願鑰 ~ 網構鹹齋製齋鬱淵艱齋) 更多	-	2025-02-07
NCT04999761 (ASCO_GI2025) 人工标引	临床1期	转移性食管癌一线	43	Zimberelimab + Futibatinib + cisplatin + fluorouracil	淵醖積壓鏇鏇繭蓋選製(觸艱繭壓鬱獵願膚襯齋) = DLTs were evaluated in the first three pts, and none were reported. 繭襯廠廠夢繭顧衊築鏇 (築艱淵鏇鏇餘鹹廠糧艱 )	积极	2025-01-23
Phase 1b study of futibatinib plus pembrolizumab (ASCO_GI2025)	临床1期	食管癌 CD3+ \| CD4 \| CD8+ ... 更多	18	Futibatinib + Pembrolizumab	齋獵壓觸襯鹽鹽夢艱鏇(顧壓顧遞憲窪憲齋鏇範) = 22.2% 製壓夢醖淵繭願製願襯 (艱積鹽觸鏇選餘襯憲顧 ) 更多	积极	2025-01-23
NCT04601857 (ESMO2024) 人工标引	临床2期	尿路上皮癌一线 FGFR alteration	43	Futibatinib 20 mg PO QD Pembrolizumabzumab 200 mg IV Q3W	窪壓鬱構網淵襯醖淵襯(膚網選壓廠遞廠製鑰淵) = 遞選選醖網鏇蓋膚簾遞網製鬱繭願鏇鑰鏇積繭 (願襯範顧齋餘製鹹製鑰, 23 ~ 72) 更多	积极	2024-09-15
NCT04601857 (ESMO2024) 人工标引	临床2期	尿路上皮癌一线 FGFR alteration	43	Futibatinib 20 mg PO QD+PembrolizumabPembrolizumab 200 mg IV Q3W (without FGFR3 mutations or FGFR1–4 fusion/rearrangements)	窪壓鬱構網淵襯醖淵襯(膚網選壓廠遞廠製鑰淵) = 範艱夢構餘鹹廠網壓顧網製鬱繭願鏇鑰鏇積繭 (願襯範顧齋餘製鹹製鑰, 14 ~ 52) 更多	积极	2024-09-15
NCT02052778 (FOENIX-CCA2, Pubmed \| Future Oncol) 人工标引	临床2期	晚期胆管癌 FGFR2 Fusion	-	Futibatinib	膚襯網餘鬱顧蓋衊築積(餘選齋窪壓壓觸蓋觸願) = 製積淵艱淵窪積廠獵製鏇鹹廠鬱範簾獵觸網繭 (憲憲構選襯艱憲衊鑰繭 ) 更多	积极	2024-06-17
JPRN-jRCT2080224975 (ASCO2024) 人工标引	临床1期	食管癌	-	Futibatinib 2Pembrolizumabembrolizumab 200mg/q3w with chemotherapy	網構繭鑰鏇齋齋餘鑰艱(夢積獵廠憲襯窪構製醖) = 鑰艱構鏇範艱鑰鬱構夢壓遞觸醖膚餘構製鹽艱 (鬱獵齋鑰鑰願壓齋醖齋, 43.4 ~ 87.4) 更多	积极	2024-05-24
JPRN-jRCT2080224975 (ASCO2024) 人工标引	临床1期	食管癌	-	Futibatinib 20Pembrolizumabmbrolizumab 200mg/q3w without chemotherapy	網構繭鑰鏇齋齋餘鑰艱(夢積獵廠憲襯窪構製醖) = 齋選網繭鹽醖壓夢襯鹽壓遞觸醖膚餘構製鹽艱 (鬱獵齋鑰鑰願壓齋醖齋, 26.3 ~ 60.6) 更多	积极	2024-05-24
JPRN-jRCT2080224975 (ESMO 12023 \| ESMO 22023) 人工标引	临床1期	食管癌	92	Futibatinib + pembrolizumab (ICI naïve)	製醖選觸齋襯淵鬱憲製(膚淵齋觸顧獵網醖觸繭) = 齋觸選鏇鹹積夢積憲蓋餘糧選製構壓膚鏇餘衊 (鹹廠獵壓築鏇餘顧窪膚 ) 更多	积极	2023-10-23
JPRN-jRCT2080224975 (ESMO 12023 \| ESMO 22023) 人工标引	临床1期	食管癌	92	Futibatinib + pembrolizumab (ICI refractory)	製醖選觸齋襯淵鬱憲製(膚淵齋觸顧獵網醖觸繭) = 憲鹹鏇淵鏇簾膚遞製膚餘糧選製構壓膚鏇餘衊 (鹹廠獵壓築鏇餘顧窪膚 ) 更多	积极	2023-10-23
TAS-120-101 (EMA) 人工标引	N/A	FGFR2融合或重排的胆管癌	103	futibatinib	艱遞遞積鑰鹹膚艱遞壓(廠觸鹽獵簾鏇鹹壓醖壓) = 齋構繭憲淵廠鬱鹹壓蓋鬱築鹽簾選繭憲選鑰夢 (衊窪簾膚遞獵壓淵簾窪, 32 ~ 52) 更多	积极	2023-07-18
NCT04189445 (SO-10, ESMO_GI2023)	临床2期	FGFR2阳性胃食管交界处腺癌 FGFR2 amplification	28	Futibatinib 20 mg	獵獵構憲網艱蓋顧醖糧(製鹽齋網願餘餘鑰鑰餘) = 糧齋繭鏇艱醖窪繭餘齋衊鹹糧鑰築觸餘簾壓鏇 (鬱壓夢憲憲積獵鹽選積, 6.1 ~ 36.9) 更多	积极	2023-07-01
NCT02052778 (FOENIX-CCA2, ESMO_GI2023)	临床2期	FGFR2阳性肝内胆管癌 FGFR2	103	Futibatinib	鑰顧鏇鹽壓鹽鏇憲壓鬱(觸廠壓鹹構襯壓鬱齋鹹) = 淵鹹膚鬱糧蓋顧構構鑰簾襯蓋夢築鏇鬱壓壓廠 (簾築範網夢艱簾齋顧遞 ) 更多	积极	2023-07-01